Phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer.
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil; Mitomycin
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TUXEDO
- 06 Jun 2017 Combined results of phases I/II, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 09 Mar 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
- 11 Feb 2016 Accrual to date is 31% according to United Kingdom Clinical Research Network record